logo
Plus   Neg
Share
Email

Bechtle FY17 EBT, Revenue Rise - Quick Facts

Information technology company Bechtle AG (BC8G) on Friday reported 12 percent growth in its earnings before taxes or EBT for the fiscal year 2017, while revenues grew over 15 percent.

The Group's EBT for the year rose about 12 percent from last year to 163 million euros, while EBT margin was 4.6 percent.

Revenue for the year increased 15 percent from the prior year to around 3.57 billion euros.

The company noted that the IT group showed double-digit growth rates across all four quarters of 2017.

"We were able to keep up our excellent momentum throughout the year, which also enabled us to compensate extraordinary items to the amount of EUR4.5m, which had a positive effect on earnings in the previous year," Dr Thomas Olemotz, CEO of Bechtle AG, said.

"At the same time, we continued to invest in numerous strategic projects to further develop our top-notch position in the European IT market," Olemotz added.

Bechtle will publish its full, audited financial statements for the 2017 fiscal year on Friday, 16 March 2018.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
RELATED NEWS
Trade BC8G now with 
Follow RTT